Updated just now · Live
Stock analysis, price data, and AI-powered insights for Zymeworks Inc (ZYME).
Zymeworks Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for ZYME.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). ZYME Stock Intelligence Report. [stoxpulse.com/stocks/zyme]
Disclaimer: The information on this page about Zymeworks Inc (ZYME) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Zymeworks Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Zymeworks Presents Data On Six Poster Presentation...
4d ago
Zymeworks Presents New Preclinical Data at AACR 20...
4d ago
StoxPulse AI results for ZYME: Pulse Score 53/100. Primary sentiment trends from 3 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$1.99B
P/E Ratio
—
EPS
$-0.26
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Zymeworks Presents Data On Six Poster Presentations Regarding New Preclinical Data From Its Antibody-Drug Conjugate, Payload Development Programs At American Association For Cancer Research Annual Meeting 2026
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026